Seminars in Nuclear Medicine
Volume 35, Issue 3 , Pages 186-196 , July 2005

Evaluation of Therapy for Lymphoma

  • Guy Jerusalem, MD, PhD

      Affiliations

    • Division of Medical Oncology, Department of Medicine, University of Liège, Liège, Belgium.
    • Corresponding Author InformationAddress reprint requests to Guy Jerusalem, MD, PhD, Medical Oncology, CHU Sart Tilman, B35, B-4000 - Liege 1, Belgium.
    • ,
  • Roland Hustinx, MD, PhD

      Affiliations

    • Division of Nuclear Medicine, Department of Medicine, University of Liège, Liège, Belgium.
    • ,
  • Yves Beguin, MD, PhD

      Affiliations

    • Division of Medical Oncology, Department of Medicine, University of Liège, Liège, Belgium.
    • ,
  • Georges Fillet, MD, PhD

      Affiliations

    • Division of Medical Oncology, Department of Medicine, University of Liège, Liège, Belgium.

References 

  1. Front D , Israel O . The role of Ga-67 scintigraphy in evaluating the results of therapy of lymphoma patients . Semin Nucl Med . 1995;25:60–71
  2. Jerusalem G , Hustinx R , Beguin Y , et al.   PET scan imaging in oncology . Eur J Cancer . 2003;39:1525–1534
  3. Rini JN , Manalili EY , Hoffman MA , et al.   F-18 FDG versus Ga-67 for detecting splenic involvement in Hodgkin’s disease . Clin Nucl Med . 2002;27:572–577
  4. Kostakoglu L , Leonard JP , Kuji I , et al.   Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma . Cancer . 2002;94:879–888
  5. Wirth A , Seymour JF , Hicks RJ , et al.   Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin’s disease and non-Hodgkin’s lymphoma . Am J Med . 2002;112:262–268
  6. Bar-Shalom R , Yefremov N , Haim N , et al.   Camera-based FDG PET and 67Ga SPECT in evaluation of lymphoma (Comparative study) . Radiology . 2003;227:353–360
  7. Friedberg JW , Fischman A , Neuberg D , et al.   FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma (A blinded comparison) . Leuk Lymphoma . 2004;45:85–92
  8. Sasaki M , Kuwabara Y , Koga H , et al.   Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma . Ann Nucl Med . 2002;16:337–345
  9. Shen YY , Kao A , Yen RF . Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma . Oncol Rep . 2002;9:321–325
  10. Van Den Bossche B , Lambert B , De Winter F , et al.   18FDG PET versus high-dose 67Ga scintigraphy for restaging and treatment follow-up of lymphoma patients . Nucl Med Commun . 2002;23:1079–1083
  11. Jerusalem G , Beguin Y , Fassotte MF , et al.   Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin’s disease and non-Hodgkin’s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging . Blood . 1999;94:429–433
  12. Jerusalem G , Beguin Y , Fassotte MF , et al.   Early detection of relapse by whole-body positron emission tomography (PET) in the follow-up of patients with Hodgkin’s disease (HD) . Ann Oncol . 2003;14:123–130
  13. Elstrom R , Guan L , Baker G , et al.   Utility of FDG-PET scanning in lymphoma by WHO classification . Blood . 2003;101:3875–3876
  14. Jerusalem G , Warland V , Najjar F , et al.   Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin’s disease and non-Hodgkin’s lymphoma . Nucl Med Commun . 1999;20:13–20
  15. Jerusalem G , Beguin Y , Najjar F , et al.   Positron emission tomography (PET) with 18F-Fluorodeoxyglucose (18F-FDG) for the staging of low grade non-Hodgkin’s lymphoma (NHL) . Ann Oncol . 2001;825–830
  16. Jerusalem G , Beguin Y , Fassotte MF , et al.   Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin’s disease . Haematologica . 2001;86:266–273
  17. Jerusalem G , Beguin Y . Positron emission tomography in non-Hodgkin’s lymphoma (NHL) (Relationship between tracer uptake and pathological findings, including preliminary experience in the staging of low-grade NHL) . Clin Lymphoma . 2002;3:56–61
  18. Dobert N , Menzel C , Hamscho N , et al.   Atypical thoracic and supraclavicular FDG-uptake in patients with Hodgkin’s and non-Hodgkin’s lymphoma . Q J Nucl Med Mol Imaging . 2004;48:33–38
  19. Jerusalem G, Hustinx R: Nuclear Medicine, in Canellos G, Lister TA, Young B (eds): The Lymphomas (ed 2). New York, Elsevier (in press)
  20. Zijlstra JM , Hoekstra OS , Raijmakers PG , et al.   18FDG positron emission tomography versus 67Ga scintigraphy as prognostic test during chemotherapy for non-Hodgkin’s lymphoma . Br J Haematol . 2003;123:454–462
  21. Jerusalem G , Warland V , Beguin Y , et al.   Accuracy of end of treatment 18F-FDG PET for predicting relapse in patients with Hodgkin’s disease (Hd) and non-Hodgkin’s lymphoma (Nhl) . Proc Am Soc Clin Oncol . 2003;22:572; (abstr 2299)
  22. Mikosch P , Gallowitsch HJ , Zinke-Cerwenka W , et al.   Accuracy of whole-body 18F-FDG-PET for restaging malignant lymphoma . Acta Med Austr . 2003;30:41–47
  23. Hueltenschmidt B , Sautter-Bihl ML , Lang O , et al.   Whole body positron emission tomography in the treatment of Hodgkin disease . Cancer . 2001;91:302–310
  24. Bangerter M , Moog F , Griesshammer M , et al.   Role of whole body FDG-PET imaging in predicting relapse of malignant lymphoma in patients with residual masses after treatment . Radiography . 1999;5:155–163
  25. Weihrauch MR , Re D , Scheidhauer K , et al.   Thoracic positron emission tomography using (18)F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease . Blood . 2001;98:2930–2934
  26. Panizo C , Perez-Salazar M , Bendandi M , et al.   Positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual Hodgkin’s disease mediastinal masses . Leuk Lymphoma . 2004;45:1829–1833
  27. Glatz S , Kotzerke J , Moog F , et al.   Vortauschung eines mediastinalen Non-Hodgkin-Lymphomrezidivs durch diffuse Thymushyperplasie im 18F-FDG-PET . Fortschr Rontgenstr . 1996;165:309–310
  28. Weinblatt ME , Zanzi I , Belakhlef A , et al.   False-positive FDG-PET imaging of the thymus of a child with Hodgkin’s disease . J Nucl Med . 1997;38:888–890
  29. Sandherr M , von Schilling C , Link T , et al.   Pitfalls in imaging Hodgkin’s disease with computed tomography and positron emission tomography using fluorine-18-fluorodeoxyglucose . Ann Oncol . 2001;12:719–722
  30. de Wit M , Bumann D , Beyer W , et al.   Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma . Ann Oncol . 1997;8(suppl 1):S57–S60
  31. Cremerius U , Fabry U , Neuerburg J , et al.   Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma . Nucl Med Commun . 1998;19:1055–1063
  32. Weidmann E , Baican B , Hertel A , et al.   Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin’s disease . Leuk Lymph . 1999;34:545–551
  33. de Wit M , Bohuslavizki KH , Buchert R , et al.   18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin’s lymphoma . Ann Oncol . 2001;12:29–37
  34. Yoon SN , Park CH , Kim MK , et al.   False-positive F-18 FDG gamma camera positron emission tomographic imaging resulting from inflammation of an anterior mediastinal mass in a patient with non-Hodgkin’s lymphoma . Clin Nucl Med . 2001;26:461–462
  35. Zinzani PL , Fanti S , Battista G , et al.   Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients . Br J Cancer . 2004;91:850–854
  36. Dittmann H , Sokler M , Kollmannsberger C , et al.   Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin’s lymphoma . Oncol Rep . 2001;8:1393–1399
  37. de Hemricourt E , De Boeck K , Hilte F , et al.   Sarcoidosis and sarcoid-like reaction following Hodgkin’s disease. Report of two cases . Mol Imaging Biol . 2003;5:15–19
  38. Bomanji JB , Syed R , Brock C , et al.   Challenging cases and diagnostic dilemmas: Case 2. Pitfalls of positron emission tomography for assessing residual mediastinal mass after chemotherapy for Hodgkin’s disease . J Clin Oncol . 2002;20:3347–3349
  39. Naumann R , Beuthien-Baumann B , Fischer R , et al.   Simultaneous occurence of Hodgkin’s lymphoma and eosinophilic granuloma—a potential pitfall in PET imaging . Clin Lymphoma . 2002;3:121–124
  40. Cheong KA , Rodgers NG , Kirkwood ID . Erythema nodosum associated with diffuse, large B-cell non-Hodgkin lymphoma detected by FDG PET . Clin Nucl Med . 2003;28:652–654
  41. Becherer A , Mitterbauer M , Jaeger U , et al.   Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation . Leukemia . 2002;16:260–267
  42. Lorenzen J , de Wit M , Buchert R , et al.   Granulation tissue (pitfall in therapy control with F-18-FDG PET after chemotherapy) . Nuklearmedizin . 1999;38:333–336
  43. Naumann R , Vaic A , Beuthien-Baumann B , et al.   Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin’s disease and non-Hodgkin’s lymphoma . Br J Haematol . 2001;115:793–800
  44. Armitage JO , Weisenburger DD , Hutchins M , et al.   Chemotherapy for diffuse large-cell lymphoma—rapidly responding patients have more durable remissions . J Clin Oncol . 1986;4:160–164
  45. Engelhard M , Meusers P , Brittinger G , et al.   Prospective multicenter trial for the response-adapted treatment of high-grade malignant non-Hodgkin’s lymphomas (Updated results of the COP-BLAM/IMVP-16 protocol with randomized adjuvant radiotherapy) . Ann Oncol . 1991;2(Suppl 2):177–180
  46. Haq R , Sawka CA , Franssen E , et al.   Significance of a partial or slow response to front-line chemotherapy in the management of intermediate-grade or high-grade non-Hodgkin’s lymphoma (A literature review) . J Clin Oncol . 1994;12:1074–1084
  47. Rahmouni A , Tempany C , Jones R , et al.   Lymphoma (Monitoring tumor size and signal intensity with MR imaging) . Radiology . 1993;188:445–451
  48. Front D , Bar-Shalom R , Mor M , et al.   Aggressive non-Hodgkin lymphoma (Early prediction of outcome with 67Ga scintigraphy) . Radiology . 2000;214:253–257
  49. Janicek M , Kaplan W , Neuberg D , et al.   Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin’s lymphoma treated with high-dose CHOP chemotherapy . J Clin Oncol . 1997;15:1631–1637
  50. Gasparini M , Bombardieri E , Castellani M , et al.   Gallium-67 scintigraphy evaluation of therapy in non-Hodgkin’s lymphoma . J Nucl Med . 1998;39:1586–1590
  51. Kaplan WD , Jochelson MS , Herman TS , et al.   Gallium-67 imaging (A predictor of residual tumor viability and clinical outcome in patients with diffuse large-cell lymphoma) . J Clin Oncol . 1990;8:1966–1970
  52. Romer W , Hanauske AR , Ziegler S , et al.   Positron emission tomography in non-Hodgkin’s lymphoma (Assessment of chemotherapy with fluorodeoxyglucose) . Blood . 1998;91:4464–4471
  53. Mikhaeel NG , Timothy AR , O’Doherty MJ , et al.   18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin’s Lymphoma-comparison with CT . Leuk Lymphoma . 2000;39:543–553
  54. Jerusalem G , Beguin Y , Fassotte MF , et al.   Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin’s lymphoma . Haematologica . 2000;85:613–618
  55. Kostakoglu L , Coleman M , Leonard JP , et al.   PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease . J Nucl Med . 2002;43:1018–1027
  56. Spaepen K , Stroobants S , Dupont P , et al.   Early restaging positron emission tomography with (18)F- fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma . Ann Oncol . 2002;13:1356–1363
  57. Torizuka T , Nakamura F , Kanno T , et al.   Early therapy monitoring with FDG-PET in aggressive non-Hodgkin’s lymphoma and Hodgkin’s lymphoma . Eur J Nucl Med Mol Imaging . 2004;31:22–28
  58. Young H , Baum R , Cremerius U , et al.  European Organization for Research and Treatment of Cancer (EORTC) PET Study Group   Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography (Review and 1999 EORTC recommendations) . Eur J Cancer . 1999;35:1773–1782
  59. Spaepen K , Stroobants S , Dupont P , et al.   [(18)F]FDG PET monitoring of tumour response to chemotherapy (Does [(18)F]FDG uptake correlate with the viable tumour cell fraction?) . Eur J Nucl Med Mol Imaging . 2003;30:682–688
  60. Philip T , Guglielmi C , Hagenbeek A , et al.   Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma . N Engl J Med . 1995;333:1540–1545
  61. Anselmo AP , Meloni G , Cavalieri E , et al.   Conventional salvage chemotherapy vs. high-dose therapy with autografting for recurrent or refractory Hodgkin’s disease patients . Ann Hematol . 2000;79:79–82
  62. Spaepen K , Stroobants S , Dupont P , et al.   Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation . Blood . 2003;102:53–59
  63. Cremerius U , Fabry U , Wildberger JE , et al.   Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin’s lymphoma . Bone Marrow Transplant . 2002;30:103–111
  64. Schot B , van Imhoff G , Pruim J , et al.   Predictive value of early 18F-fluoro-deoxyglucose positron emission tomography in chemosensitive relapsed lymphoma . Br J Haematol . 2003;123:282–287
  65. Filmont JE , Czernin J , Yap C , et al.   Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation . Chest . 2003;124:608–613
  66. Coiffier B . How to interpret the radiological abnormalities that persist after treatment in non-Hodgkin’s lymphoma patients? . Ann Oncol . 1999;10:1141–1143
  67. Radford JA , Cowan RA , Flanagan M , et al.   The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin’s disease . J Clin Oncol . 1988;6:940–946
  68. Glenn LD , Kumar PP . The residual mediastinal mass following radiation therapy for Hodgkin’s disease . Am J Clin Oncol . 1991;14:16–24
  69. Coiffier B , Gisselbrecht C , Vose JM , et al.   Prognostic factors in aggressive malignant lymphomas: Description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d’Etudes des Lymphomes Agressifs . J Clin Oncol . 1991;9:211–219
  70. Jochelson M , Mauch P , Balikian J , et al.   The significance of the residual mediastinal mass in treated Hodgkin’s disease . J Clin Oncol . 1985;3:637–640
  71. Israel O , Front D , Lam M , et al.   Gallium 67 imaging in monitoring lymphoma response to treatment . Cancer . 1988;61:2439–2443
  72. Surbone A , Longo DL , DeVita VT , et al.   Residual abdominal masses in aggressive non-Hodgkin’s lymphoma after combination chemotherapy (Significance and management) . J Clin Oncol . 1988;6:1832–1837
  73. Canellos GP . Residual mass in lymphoma may not be residual disease . J Clin Oncol . 1988;6:931–933
  74. Segall GM . FDG PET imaging in patients with lymphoma (A clinical perspective) . J Nucl Med . 2001;42:609–610
  75. Zinzani PL , Magagnoli M , Chierichetti F , et al.   The role of positron emission tomography (PET) in the management of lymphoma patients . Ann Oncol . 1999;10:1181–1184
  76. Mikhaeel NG , Timothy AR , Hain SF , et al.   18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas . Ann Oncol . 2000;11:S147–S150
  77. Foo SS , Mitchell PL , Berlangieri SU , et al.   Positron emission tomography scanning in the assessment of patients with lymphoma . Intern Med J . 2004;34:388–397
  78. Spaepen K , Stroobants S , Dupont P , et al.   Can positron emission tomography with [18F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin’s disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? . Br J Haematol . 2001;115:272–278
  79. Guay C , Lepine M , Verreault J , et al.   Prognostic value of PET using 18F-FDG in Hodgkin’s disease for posttreatment evaluation . J Nucl Med . 2003;44:1225–1231
  80. Spaepen K , Stroobants S , Dupont P , et al.   Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin’s lymphoma (Is [18F]FDG-PET a valid alternative to conventional diagnostic methods?) . J Clin Oncol . 2001;19:414–419
  81. Maisey NR , Hill ME , Webb A , et al.   Are 18fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses? . Eur J Cancer . 2000;36:200–206
  82. Cremerius U , Fabry U , Neuerburg J , et al.   Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma . Nuklearmedizin . 2001;40:23–30
  83. Lavely WC , Delbeke D , Greer JP , et al.   FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy . Int J Radiat Oncol Biol Phys . 2003;57:307–315
  84. Lang O , Bihl H , Hultenschmidt B , et al.   Clinical relevance of positron emission tomography (PET) in treatment control and relapse of Hodgkin’s disease . Strahlenther Onkol . 2001;177:138–144
  85. Cremerius U , Fabry U , Kroll U , et al.   Clinical value of FDG PET for therapy monitoring of malignant lymphoma—results of a retrospective study in 72 patients . Nuklearmedizin . 1999;38:24–30
  86. Torizuka T , Zasadny KR , Kison PV , et al.   Metabolic response of non-Hodgkin’s lymphoma to 131I-anti-B1 radioimmunotherapy (Evaluation with FDG PET) . J Nucl Med . 2000;41:999–1005
  87. Jerusalem G, Hustinx R, Beguin Y, et al: Whole-body positron emission tomography using 18F-fluorodeoxyglucose for staging and response assessment in Hodgkin’s disease, in Colombus F (ed): Progress in Hodgkin’s Disease Research. Nova Science (in press)

PII: S0001-2998(05)00014-0

doi: 10.1053/j.semnuclmed.2005.02.004

Seminars in Nuclear Medicine
Volume 35, Issue 3 , Pages 186-196 , July 2005

Article Tools

* Image Usage & Resolution